Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Rifampicin on the Pharmacokinetics of BI 425809 in Healthy Male Subjects
NCT03082183Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2017
- Primary completion
- Jun 2017
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iclepertin, sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Plasma Concentration-time Curve From 0 to 168 Hours Time Point of BI 425809 and Maximum Concentration of BI 425809 in Plasma at 168 hours. Started Mar 2017; status: completed.
02
Drugs
iclepertin
Beyond the preview
Go deeper on NCT03082183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03082183.